Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Core One Labs Inc. C.COOL

Alternate Symbol(s):  CLABF

Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. The Company, through its wholly owned subsidiary, Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its subsidiary Akome Biotech Ltd., and three provisional patents under its other subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods. It also holds an interest in four medical clinics.


CSE:COOL - Post by User

Comment by SCORPION34on Feb 07, 2021 3:04pm
122 Views
Post# 32496436

RE:Great News 🚀🚀🚀

RE:Great News 🚀🚀🚀COOL is rapidly becoming a leader in the Psychedelic Medicine space. I would say they are much further along in their development compared to their peers. They are about to produce cost effective biosynthesized psilocybin + have a micro-dosing thin strip technology + medical clinincs in Canada and soon in the US + a potential Nasdaq listing. All for a market cap of $77 million. This is way underpriced. Should be trading 3-4 times higher IMO. 

The Conference Call on Wednesday should shed light on just how far advanced we are as a company. I encourage everyone to listen. 
<< Previous
Bullboard Posts
Next >>